A longtime leader in healthcare improvement, we’re developing new ways to revolutionize the industry.

We deliver transformative solutions that power real results. See how we can help.

Optimizing Supply Chain
Integrating Pharmacy
Maximizing Value-Based Care
Awards and Recognition

Transforming healthcare is more than our objective, it’s in our DNA. We’re dedicated to ensuring better health is just the beginning.


Guided by our values, our employees work every day to make meaningful differences in healthcare. At the core of what we do is our most valuable resource - our people. Learn more about us.

Board of Directors
Speakers Bureau

Premier is more than a GPO. Combining robust analytics with consulting and advocacy, we’re changing the healthcare landscape for the better.  

Collective purchasing power lowers costs across your organization.

Intelligence plus unparalleled analytics equals data-driven solutions.

It’s only impossible until it’s not. Premier and our team of experts are transforming care delivery.

Work with Premier members to lower costs, improve quality and safety and succeed in value-based care.

A voice for better healthcare policy is a voice for you.  

Working closely with our members, we’re developing products and services to solve your most complex challenges.

Lower costs, greater efficiencies and a healthier bottom line.

Proven practices that result in better outcomes.

Intersecting specialty drugs with better management and data-driven best practices.

Controlling your future with integrated care delivery practices.

More savings and ROI is a win-win.

Data diving to deliver insights you can act on.

Supporting healthcare transformation through the generation of real-world evidence.

Working closely with our members, we're developing products and services to solve your most complex challenges.

Our most recent insights, articles and more, all in one place.  

Discover what leading healthcare providers are achieving through Premier membership.

Stay informed with our white papers, webinars and e-books.

Browse our blog for a taste of what’s new and what’s next in healthcare.

Premier’s perspectives have been solicited by nationally renowned publications. Read on.

Read Premier’s latest announcements.

Catch our policy statements and perspectives on the latest in DC.

Compelling stories from the front lines of America’s health systems.

The proactive, predictive and behind-the-scenes insights you need to stay ahead in healthcare delivered monthly to your inbox.

The Unintended Consequences of a Drug Quality Rating System

Published in: Healthcare Innovation


The U.S. Food and Drug Administration (FDA) has been pursuing a framework for a pharmaceutical manufacturing site rating system, the Quality Management Maturity (QMM) program, which aims to improve operations and curb drug shortages.

Greater focus on supplier quality incentives and rewards, including payment for reliably meeting providers’ supply requirements, is key to incenting manufacturers to participate in healthy and sustainable pharmaceutical markets. However, a rating system like the QMM may generate unintended downstream consequences that exacerbate drug shortages and create new operational challenges for U.S. healthcare providers.

A Rating System Approach Picks Winners and Losers

The FDA recently formed a multidisciplinary working group on the QMM rating system, stating that ratings could provide intelligence on production facilities’ performance and robustness, and support flexibility for manufacturers to make post approval manufacturing changes with less regulatory oversight.

Currently lacking are the necessary details for operationalizing and implementing a rating system, including how ratings are managed and how facilities that receive any score under the top rating will be managed in the current regulatory environment.

For instance, such a system may be inherently subject to bias and proposes to assign a rating or ranking to every FDA-approved drug manufacturing site around the globe. Under this model, one single drug with the same dosage and strength produced by same manufacturer with the same National Drug Code (NDC), in theory, could accrue a different quality rating based on the specific facility at which it was produced – creating confusion, little parity and potentially the need for multiple labels to distinguish between the 5-star and 3-star “twin” products.

A quality rating system can also unintentionally select winners and losers in an already-constrained environment – further increasing barriers to entry and discouraging competition. With the likelihood for pricing variability on high versus low-rated products, many lesser-rated manufacturers may make the difficult decision of reducing production or exiting the market entirely – two actions that can, and have, triggered drug shortages.

Click here to read the full byline published in Healthcare Innovation

Login Register Change Registration